Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Inovio

- PMLiVE

Pfizer and BioNTech initiate phase 2 study of ‘enhanced’ COVID-19 vaccine

The vaccine is based on a version of the spike protein that the companies hope will offer better and broader protection against the virus

- PMLiVE

Pfizer and BioNTech speak out against CureVac suit over patents for COVID-19 vaccines

The civil suit claims that once CureVac had withdrawn its vaccine candidate, the company was unable to garner 50% efficacy in a late-stage trial

- PMLiVE

Fauci addresses need for pan-coronavirus and intranasal vaccines to combat COVID-19 variants

Vaccine manufacturers have been urged to move forward with producing Omicron-targeting formulations

- PMLiVE

FDA grants priority review to Biogen’s tofersen for genetic form of ALS

The approval follows a failed phase 3 study, but the treatment showed promise in patients with SOD1-ALS

Trust and transparency in Pharma & healthcare: impact of the COVID-19 pandemic

While it is obvious that trust in life science and healthcare companies is suboptimal, exactly how to improve the public’s trust is unclear...

Impetus Digital

- PMLiVE

WHO updates COVID-19 vaccination strategy to reach unprotected populations

The update raises targets to vaccinate 100% of healthcare workers and 100% of the highest risk populations with primary and booster doses

- PMLiVE

Gilead’s COVID-19 drug Veklury recommends for approval by CHMP

If approved by the EC, Veklury will become the only direct-acting antiviral with full marketing authorisation in the EU

- PMLiVE

Sandoz’s biosimilar medicine application accepted by FDA

If approved, the higher concentration formulation could decrease the number of injections required for patients currently receiving a lower dose of Hyrimoz

- PMLiVE

Biopharma industry launches Berlin Declaration to ensure equal access during future pandemics

The Declaration outlines a framework that could help to ensure that lower-income countries receive pandemic vaccines and treatments

- PMLiVE

FDA approves Incyte’s Opzelura for vitiligo

It is the first and only FDA-approved product for repigmentation in patients with nonsegmental vitiligo

- PMLiVE

Roche’s diagnostic test for Alzheimer’s receives FDA Breakthrough Device Designation

Alzheimer's affects more than 55 million people globally and is the most common form of dementia

- PMLiVE

COVID-19 pandemic ‘reversed’ progress made in fight against antimicrobial resistance in US, new CDC report reveals

The report concluded that resistant hospital-onset infections and deaths both increased at least 15% during the first year of the pandemic

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links